RT Journal Article
T1 In vivo staging of regional amyloid deposition predicts functional conversion in the preclinical and prodromal phases of Alzheimer's disease.
A1 Teipel, Stefan J
A1 Dyrba, Martin
A1 Chiesa, Patrizia A
A1 Sakr, Fatemah
A1 Jelistratova, Irina
A1 Lista, Simone
A1 Vergallo, Andrea
A1 Lemercier, Pablo
A1 Cavedo, Enrica
A1 Habert, Marie Odile
A1 Dubois, Bruno
A1 Hampel, Harald
A1 Grothe, Michel J
A1 INSIGHT-preAD study group and for the Alzheimerś Disease Neuroimaging Initiative, 
K1 Amyloid
K1 Dementia
K1 Longitudinal study
K1 MCI
K1 Subjective cognitive decline
AB We tested the usefulness of a regional amyloid staging based on amyloid sensitive positron emission tomography to predict conversion to cognitive impairment and dementia in preclinical and prodromal Alzheimer's disease (AD). We analyzed 884 cases, including normal controls, and people with subjective cognitive decline or mild cognitive impairment (MCI), from the Alzheimer's Disease Neuroimaging Initiative with a maximum follow-up of 6 years and 318 cases with subjective memory complaints with a maximum follow-up time of three years from the INveStIGation of AlzHeimer's PredicTors cohort (INSIGHT-preAD study). Cox regression showed a significant association of regional amyloid stages with time to conversion from a cognitively normal to an MCI, and from an MCI to a dementia status. The most advanced amyloid stages identified very-high-risk groups of conversion. All results were robustly replicated across the independent samples. These findings indicate the usefulness of regional amyloid staging for identifying preclinical and prodromal AD cases at very high risk of conversion for future amyloid targeted trials.
YR 2020
FD 2020-03-17
LK http://hdl.handle.net/10668/15374
UL http://hdl.handle.net/10668/15374
LA en
DS RISalud
RD Apr 8, 2025